Form 8-K - Current report:
SEC Accession No. 0001193125-25-053541
Filing Date
2025-03-13
Accepted
2025-03-13 08:49:28
Documents
15
Period of Report
2025-03-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d815684d8k.htm   iXBRL 8-K 56664
2 EX-99.1 d815684dex991.htm EX-99.1 8131
6 GRAPHIC g815684g0313054259371.jpg GRAPHIC 2257
  Complete submission text file 0001193125-25-053541.txt   200309

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA plrx-20250312.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE plrx-20250312_lab.xml EX-101.LAB 17980
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE plrx-20250312_pre.xml EX-101.PRE 11260
17 EXTRACTED XBRL INSTANCE DOCUMENT d815684d8k_htm.xml XML 3729
Mailing Address 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Filer) CIK: 0001746473 (see all company filings)

EIN.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39303 | Film No.: 25733981
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)